Bioproduction of Neospora caninum: a proof-of- concept towards a scalable serum-free process
This study demonstrates the feasibility of a scalable, serum-free bioproduction process for the oncolytic protozoan *Neospora caninum* using industrial CHO-K1 cells and Advanced DMEM/F-12 medium, thereby addressing critical bottlenecks in standardization and regulatory compliance for its clinical translation as a cancer immunotherapy.